Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method

被引:45
作者
Chen, GF
Tang, YM
Green, B
Lin, DX
Guengerich, FP
Daly, AK
Caporaso, NE
Kadlubar, FF
机构
[1] Natl Ctr Toxicol Res, Div Mol Epidemiol, Jefferson, AR 72079 USA
[2] Chinese Acad Med Sci, Inst Canc, Dept Chem Etiol & Carcinogenesis, Beijing 100021, Peoples R China
[3] Beijing Union Med Coll, Beijing, Peoples R China
[4] Vanderbilt Univ, Ctr Mol Toxicol, Dept Biochem, Nashville, TN USA
[5] Univ Newcastle Upon Tyne, Sch Med, Dept Pharmacol Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[6] Natl Canc Inst, Genet Epidemiol Branch, Bethesda, MD USA
来源
PHARMACOGENETICS | 1999年 / 9卷 / 03期
关键词
genetic polymorphism; restriction fragment length polymorphism; DNA sequencing; cytochrome P450;
D O I
10.1097/00008571-199906000-00007
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Human cytochrome P450 2A6 (CYP2A6) has been shown to metabolically activate carcinogens and mutagens, Genetic polymorphisms for CYP2A6 have been reported previously in different ethnic groups using a two-step polymerase chain reaction (PCR) method to identify CYP2A6*1, CYP2A6*2 and CYP2A6*3. Moreover, a new truncated allele has been recently identified in a Japanese population. We report here a one-step PCR amplification of the CYP2A6 gene from human genomic DNA and the detection of intact CYP2A6 alleles by restriction enzyme digestion. The diagnostic exon (exon 3) of the CYP2A6 gene was amplified from human genomic DNA with a primer pair. The forward primer is unique to the CYP2A6 gene, which eliminates previous problems in amplifying two highly homologous CYP2A genes, CYP2A7 and CYP2A13, in humans. The resulting PCR products (214 bp) were digested with XcmI or DdeI to detect the presence of CYP2A6*2 or CYP2A6*3 alleles, respectively. The allelic frequencies for CYP2A6*2 were 2.3% (n = 320) in the Caucasian and 0.7% (n = 71) in the Chinese populations, respectively, CYP2A6*3 allelic frequency in the Chinese population was 0.7%; while no CYP2A6*3 allele was detected in the Caucasian population, The allelic frequencies are relatively low and the reason for this discrepancy between different methods is discussed. Pharmacogenetics 9:327-332 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 17 条
[1]   GENERAL METHOD FOR ISOLATION OF HIGH MOLECULAR-WEIGHT DNA FROM EUKARYOTES [J].
BLIN, N ;
STAFFORD, DW .
NUCLEIC ACIDS RESEARCH, 1976, 3 (09) :2303-2308
[2]   A TOBACCO SMOKE-DERIVED NITROSAMINE, 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE, IS ACTIVATED BY MULTIPLE HUMAN CYTOCHROME P450S INCLUDING THE POLYMORPHIC HUMAN CYTOCHROME P4502D6 [J].
CRESPI, CL ;
PENMAN, BW ;
GELBOIN, HV ;
GONZALEZ, FJ .
CARCINOGENESIS, 1991, 12 (07) :1197-1201
[3]  
DING X, 1988, BIOCHEMISTRY-US, V29, P1322
[4]  
FERNANDEZSALGUERO P, 1995, AM J HUM GENET, V57, P651
[5]   CYP2A6 gene polymorphism and risk of liver cancer and cirrhosis [J].
Gullsten, H ;
Agundez, JAG ;
Benitez, J ;
Laara, E ;
Ladero, JM ;
DiazRubio, M ;
FernandezSalguero, P ;
Gonzalez, F ;
Rautio, A ;
Pelkonen, O ;
Raunio, H .
PHARMACOGENETICS, 1997, 7 (03) :247-250
[6]   A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin [J].
Hadidi, H ;
Zahlsen, K ;
Idle, JR ;
Cholerton, S .
FOOD AND CHEMICAL TOXICOLOGY, 1997, 35 (09) :903-907
[7]   Differential amplification kinetics for point mutation analysis by PCR [J].
Kaltenböck, B ;
Schneider, R .
BIOTECHNIQUES, 1998, 24 (02) :202-+
[8]  
Messina ES, 1997, J PHARMACOL EXP THER, V282, P1608
[9]   IDENTIFICATION OF THE HUMAN LIVER CYTOCHROME-P-450 RESPONSIBLE FOR COUMARIN 7-HYDROXYLASE ACTIVITY [J].
MILES, JS ;
MCLAREN, AW ;
FORRESTER, LM ;
GLANCEY, MJ ;
LANG, MA ;
WOLF, CR .
BIOCHEMICAL JOURNAL, 1990, 267 (02) :365-371
[10]   P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature [J].
Nelson, DR ;
Koymans, L ;
Kamataki, T ;
Stegeman, JJ ;
Feyereisen, R ;
Waxman, DJ ;
Waterman, MR ;
Gotoh, O ;
Coon, MJ ;
Estabrook, RW ;
Gunsalus, IC ;
Nebert, DW .
PHARMACOGENETICS, 1996, 6 (01) :1-42